Sun Pharma launches first branded ophthalmic product in USA

India’s largest drugmaker, Sun Pharmaceutical Industries (BSE: 524715), has launched BromSite (bromfenac ophthalmic solution) 0.075% in the US market.

A nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, BromSite will be marketed by Sun Ophthalmics, the company’s branded ophthalmic business division. BromSite is the first branded product launched by the company in the USA, following its focus on Specialty Business after the acquisition in 2015 of InSite Vision.

Approved by the US Food and Drug Administration on April 8, 2016, BromSite is the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery. Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility, absorption, bioavailability, and residence time as compared to conventional topical therapies.